>The EuroQoL EQ-5D: An Outcome Measure for use in Clinical and Economic Evaluation

Authors: Kind P.¹; Charro F.²

Source: Value in Health, Volume 1, Number 1, May 1998 , pp. 93-94(2)

Publisher: Wiley-Blackwell

Abstract:

The measurement of health outcomes is central to all evaluative studies. Clinical practice too is shaped by the need to monitor health status, and changes in health status. A prime requirement in most studies is the capacity to represent benefits (or disbenefits) in terms of a single, aggregate value. This property is typically absent from profile meausres that characterise health status in terms of separate dimension scores. EQ-5D is a generic measure that yields a single index value for health status based on self-reported problems on each of 5 dimensions-mobility, self care, usual activity, pain/discomfort, anxiety/depression. Utility weights for each of 245 health states are available. EQ-5D is one of a handful of measures recommended by the Washington Panel on Cost-Effectiveness. Elsewhere EQ-5D has received official sanction under the European Commission BIOMED programme and has been incorporated in the English National Health Survey. EQ-5D has rapidly been assimilated into clinical trials by many of the major pharmaceuticals. This workshop is designed to provide an overview of the development of EQ-5D, outlining the research proramme undertaken by the EuroQoL Group over the past 10 years; to report on its use in clinical and economic evaluation; and to detail its international take-up. It is expected that workshop attendees will be primarily researchers and analysts concerned with clinical and economic evaluation, particularly where international collaboration is involved. Thus far EQ-5D has been translated into more than 25 languages. Participation in the Workshop should provide sufficient exposure to enable all attendees to reach a balanced conclusion regarding the usefulness of EQ-5D.

Document Type: Research article

DOI: http://dx.doi.org/10.1046/j.1524-4733.1998.1100933.x

Affiliations: 1: Centre for Health Economics, University of York, York, UK 2: Centre for Health Policy and Law, Erasmus University, Rotterdam, The Netherlands

Publication date: 1998-05-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Business ,  Pharmacology ,  Therapeutics & Alternative Medicine
• By this author: Kind P. ;  Charro F.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers